{"id":"NCT00090493","sponsor":"University of Arkansas","briefTitle":"Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma","officialTitle":"UARK 2003-26, A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination With DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2004-06","primaryCompletion":"2007-07","completion":"2012-05","firstPosted":"2004-08-31","resultsPosted":"2013-06-24","lastUpdate":"2013-06-24"},"enrollment":4,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"BIOLOGICAL","name":"MAGE-A3","otherNames":[]},{"type":"BIOLOGICAL","name":"MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY","otherNames":[]}],"arms":[{"label":"MAGE-A3 and NY-ESO-1 Immunotherapy","type":"EXPERIMENTAL"}],"summary":"The hope is that the peptide vaccines will stimulate the immune system to attack and kill the myeloma cells. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.","primaryOutcome":{"measure":"The Number of Participants Experiencing a Response to the Peptide Vaccines.","timeFrame":"2 week intervals","effectByArm":[{"arm":"MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":11},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://myeloma.uams.edu/"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":4},"commonTop":[]}}